Literature DB >> 31221809

Non-tuberculous mycobacterial pulmonary disease.

Steven Cowman1,2, Jakko van Ingen3, David E Griffith4, Michael R Loebinger5,2.   

Abstract

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a challenging infection which is becoming increasingly prevalent, particularly in the elderly, for reasons which are unknown. While underlying lung disease is a well-established risk factor for NTM-PD, it may also occur in apparently healthy individuals. No single common genetic or immunological defect has been identified in this group, and it is likely that multiple pathways contribute towards host susceptibility to NTM-PD which further interact with environmental and microbiological factors leading to the development of disease.The diagnosis of NTM-PD relies on the integration of clinical, radiological and microbiological results. The clinical course of NTM-PD is heterogeneous, with some patients remaining stable without the need for treatment and others developing refractory disease associated with considerable mortality and morbidity. Treatment regimens are based on the identity of the isolated species, drug sensitivity testing (for some agents) and the severity of disease. Multiple antibiotics are typically required for prolonged periods of time and treatment is frequently poorly tolerated. Surgery may be beneficial in selected cases. In some circumstances cure may not be attainable and there is a pressing need for better regimens to treat refractory and drug-resistant NTM-PD.This review summarises current knowledge on the epidemiology, aetiology and diagnosis of NTM-PD and discusses the treatment of two of the most clinically significant species, the M. avium and M. abscessus complexes, with a focus on refractory disease and novel therapies.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 31221809     DOI: 10.1183/13993003.00250-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  43 in total

1.  Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach.

Authors:  Yang Liu; Yaoju Tan; M Mahmudul Islam; Yuanyuan Cao; Xiaoyun Lu; Sheng Zeng; H M Adnan Hameed; Peipei Zhou; Xingshan Cai; Shuai Wang; Julius N Mugweru; Guoliang Zhang; Huancai Yin; Jianxiong Liu; Eric Nuermberger; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI).

Authors: 
Journal:  J Prev Med Hyg       Date:  2019-10-15

3.  The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria.

Authors:  Lian J Pennings; Mike Marvin Ruth; Heiman F L Wertheim; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 4.  Genetic and hormonal mechanisms underlying sex-specific immune responses in tuberculosis.

Authors:  Manish Gupta; Geetha Srikrishna; Sabra L Klein; William R Bishai
Journal:  Trends Immunol       Date:  2022-07-13       Impact factor: 19.709

5.  Dissecting erm(41)-Mediated Macrolide-Inducible Resistance in Mycobacterium abscessus.

Authors:  Matthias Richard; Ana Victoria Gutiérrez; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

6.  Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.

Authors:  Matt D Johansen; Wassim Daher; Françoise Roquet-Banères; Clément Raynaud; Matthéo Alcaraz; Florian P Maurer; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies.

Authors:  Vidhisha V Sonawane; Mike M Ruth; Lian J Pennings; Elin M Svensson; Heiman F L Wertheim; Wouter Hoefsloot; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

8.  A Molecular-Beacon-Based Multiplex Real-Time PCR Assay To Distinguish Mycobacterium abscessus Subspecies and Determine Macrolide Susceptibility.

Authors:  Salvatore A E Marras; Liang Chen; Elena Shashkina; Rebecca M Davidson; Michael Strong; Charles L Daley; Barry N Kreiswirth
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948

Review 9.  Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.

Authors:  Jan-Willem Alffenaar; Anne-Grete Märtson; Scott K Heysell; Jin-Gun Cho; Asad Patanwala; Gina Burch; Hannah Y Kim; Marieke G G Sturkenboom; Anthony Byrne; Debbie Marriott; Indy Sandaradura; Simon Tiberi; Vitali Sintchencko; Shashikant Srivastava; Charles A Peloquin
Journal:  Clin Pharmacokinet       Date:  2021-03-10       Impact factor: 6.447

10.  Association of serum antibodies against the Mycobacterium avium complex and hemoptysis: a cross-sectional study.

Authors:  Hiroaki Ogata; Atsushi Moriwaki; Taisuke Nakagawa; Soichiro Sakoda; Akiko Ishimatsu; Kazuhito Taguchi; Hiroshi Aso; Hiroko Nogami; Masako Kadowaki; Yuko Tateshi; Makoto Yoshida
Journal:  BMC Infect Dis       Date:  2021-05-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.